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Abstract: Neuronal lactate uptake supports energy metabolism associated with synaptic signaling
and recovery of extracellular ion gradients following neuronal activation. Altered expression of the
monocarboxylate transporters (MCT) in temporal lobe epilepsy (TLE) hampers lactate removal into
the bloodstream. The resulting increase in parenchymal lactate levels might exert both, anti- and
pro-ictogen effects, by causing acidosis and by supplementing energy metabolism, respectively.
Hence, we assessed the contribution of lactate to the maintenance of transmembrane potassium
gradients, synaptic signaling and pathological network activity in chronic epileptic human tissue.
Stimulus induced and spontaneous field potentials and extracellular potassium concentration changes
(∆[K+]O) were recorded in parallel with tissue pO2 and pH in slices from TLE patients while blocking
MCTs by α-cyano-4-hydroxycinnamic acid (4-CIN) or D-lactate. Intrinsic lactate contributed to the
oxidative energy metabolism in chronic epileptic tissue as revealed by the changes in pO2 following
blockade of lactate uptake. However, unlike the results in rat hippocampus, ∆[K+]O recovery kinetics
and field potential amplitude did not depend on the presence of lactate. Remarkably, inhibition of
lactate uptake exerted pH-independent anti-seizure effects both in healthy rat and chronic epileptic
tissue and this effect was partly mediated via adenosine 1 receptor activation following decreased
oxidative metabolism.
Keywords: lactate; monocarboxylate transporter inhibitors; seizure; interictal activity; mesial
temporal lobe epilepsy; adenosine
1. Introduction
Under physiological conditions, brain function predominantly relies on oxidative metabolism
of glucose [1]. During extensive neuronal activation, glial glycogen stores are mobilized and surplus
lactate from the glycolysis is released via monocarboxylate transporters (MCT), hemichannels or ion
channels into the extracellular space [2–4] generating a lactate gradient between astrocytes, neurons
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and blood vessels [5]. Due to the delicate distribution pattern of MCTs on different cell types and
subcellular compartments, individual components of synaptic signaling might differentially rely on
ATP derived from the oxidative metabolism of lactate [6]. Although the general validity of astrocytic
neuronal lactate shuttle (ANLS) [7] has been a matter of debate [8], a subtle but important role for
lactate can be found in the presence of glucose in neurovascular signaling [9], synaptic transmission
and plasticity [10–14]. The low affinity isoform MCT1 is expressed in astrocytes, endothelial cells
of microvessels and on oligodendrocytes [6]. Lactate release mediated by oligodendricytic MCT1
was shown to be critical for maintenance of axonal functions [15]. MCT4 is the major MCT isoform
present on astrocytes in several brain structures, including the hippocampus. The density of MCT4
appears to be highest in the area of the astrocytic endfeet enwrapping the cerebrovasculature [16,17],
suggesting that MCT4 facilitates the removal of lactate into the circulation in order to prevent lactic
acidosis. Although MCT2 immunoreactivity has also been found on perivascular endfeet [18–20],
its high affinity for lactate (Km: 0.74 mM) and its preferential localization on dendritic post-synaptic
densities [16,21] implicates that this isoform might be responsible for the neuronal uptake and for the
metabolic support of synaptic signaling [13].
We have recently shown that intrinsic lactate supports synaptic signaling in rat hippocampal slices
and is critical for extracellular ion equilibration time course following neuronal activation. Inhibition
of the MCT2 mediated lactate transport by α-cyano-4-hydroxycynamate (4-CIN) led to a decrease
in postsynaptic action potential generation, and this effect was dependent on the activation of KATP
channels. A significant contribution of lactate to oxidative energy metabolism was evidenced by the
decrease in the baseline and stimulus induced changes in pO2 as well as by the drift in the ratio of
reduced and oxidized flavin adenine dinucleotide (FADH2/FAD+) [22].
Acute provoked epileptic seizures are associated with massive increases of glucose metabolism
in order to meet the energy demand for restoration of pathologically altered transmembrane ion
gradients [23]. The concomitant increases in parenchymal lactate levels could be both proconvulsive
by supporting energy metabolism or anticonvulsive due to the acidotic drift in tissue pH. Interictal
extracellular lactate concentration was found to be elevated in mesial temporal lobe epilepsy (mTLE)
patients when compared between the epileptogenic and the non-epileptogenic hippocampus [24]
indicating serious alterations in the lactate removal mechanisms. Indeed, the expression pattern of
several MCTs is disturbed, MCT1 was lost on microvessels and upregulated on astrocytes in the
neuropil of the hippocampal formation both in human mTLE samples and in animal models of
mTLE [25,26], while cortical MCT4 expression levels were significantly lowered in mTLE patients and
also in pilocarpine model of epilepsy [27].
Here, we tested the hypothesis that the contribution of intrinsic lactate to energy metabolism
associated with induced stimulus and epileptiform network activity are altered in chronic epileptic
tissue. In subsequent experiments, we investigated whether the effect of lactate uptake inhibitors on
network activity is exclusively mediated by the change in the extracellular pH or the activation of
adenosine 1 (A1) receptors following metabolic restriction.
2. Results
2.1. α-cyano-4-hydroxycinnamic acid (4-CIN) Decreased Stimulus Induced pO2 in Neocortical Slices from
Patients with mesial Temporal Lobe Epilepsy (mTLE)
We have previously shown that neuronal lactate uptake supports synaptic transmission and
recovery of stimulus induced transmembrane ionic gradients in the Cornu Ammonis 3 (CA3) region of
the rat hippocampus [22]. Expression pattern of monocarboxylate transporters (MCTs) is altered in
chronic epileptic tissue from mTLE patients [25,28], but it is not known, how these alterations would
affect the role of lactate as metabolic substrate. In the first set of experiments, we tried to reproduce
the findings from healthy rat hippocampus in neocortical slices from patients with mTLE. Neuronal
activation was induced by application of stimulus trains (20 Hz, 2 s) onto the white matter while
recording changes in extracellular K+ (∆[K+]O) and oxygen tension (∆pO2) in the deep neocortical
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layers V/VI. Application of 4-CIN at a concentration which preferentially blocks lactate uptake via
MCT2 (200 µM) significantly reduced stimulus induced ∆pO2 from 21.8 ± 1.2 to 15.3 ± 0.7 mmHg
(Figure 1A,B; paired t-test, p < 0.001, n = 9, 5 patients) in line with the findings in rat brain slices.
Baseline pO2 of 504.4 ± 102.7 mmHg was measured in interface chamber under 95% O2 and 5% CO2.
Despite the decrease in ∆pO2, there was no obvious change in baseline pO2 suggesting that lactate
contribution to the basal oxidative metabolism is negligible.
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Figure 1. Effects of monocarboxylate transporter (MCT) inhibition by α-cyano-4-hydroxycinnamic 
acid (4-CIN) on stimulus induced extracellular tissue oxygen changes (ΔpO2), field potential 
responses (FP), amplitude and recovery kinetics of extracellular K+ concentration changes (Δ[K+]O). 
Despite the clear effect on the stimulus induced pO2 changes neither recovery kinetics of Δ[K+]O nor 
field potential amplitude were affected by 4-CIN. (A) Sample traces of ΔpO2 (left), field potential 
transients (middle) and Δ[K+]O (right) in the presence and the absence of 4-CIN. Inhibition of the MCTs 
decreased ΔpO2 both at (B) 200 µM and (C) 500 µM 4-CIN concentration, (D,E) whereas it did not 
affect field potential amplitude and (F,G) first half recovery time of Δ[K+]O for both concentrations, 
respectively; (B–G) Variables are given on the Y-axis, categories of treatment on the X-axis. *** p < 
0.001.  
Figure 1. Effects of monocarboxylate transporter (MCT) inhibition by α-cyano-4-hydroxycinnamic acid
(4-CIN) on stimulus induced extracellular tissue oxygen changes (∆pO2), field potential responses (FP),
amplitude and recovery kinetics of extracellular K+ concentration changes (∆[K+]O). Despite the clear
effect on the stimulus induced pO2 changes neither recovery kinetics of ∆[K+]O nor field potential
amplitude were affected by 4-CIN. (A) Sample traces of ∆pO2 (left), field potential transients (middle)
and ∆[K+]O (right) in the presence and the absence of 4-CIN. Inhibition of the MCTs decreased ∆pO2
both at (B) 200 µM and (C) 500 µM 4-CIN concentration, (D,E) whereas it did not affect field potential
amplitude and (F,G) first half recovery time of ∆[K+]O for both concentrations, respectively; (B–G)
Variables are given on the Y-axis, categories of treatment on the X-axis. *** p < 0.001.
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Unlike in the rat hippocampus slices, the population spike components of the field potential
responses were not affected by inhibition of lactate uptake (2.2 ± 0.2 mV vs. 2.0 ± 0.2 mV in control
condition and during 4-CIN application respectively; Figure 1A,D; Wilcoxon signed rank test, p > 0.5,
n = 8, 5 patients). In line with the missing effect on the synaptic signaling, 4-CIN did not change the
recovery kinetics of stimulus induced ∆[K+]O (peak ∆[K+]O: 1.7 ± 0.1 mM; n = 10, 5 patients). Neither
the peak amplitude nor the 1st half decay time, 6.4 ± 0.8 vs. 6.0 ± 0.7 s, were altered (Figure 1A,F;
n = 10, 5 patients). Taking into account the potentially different equilibration times in rat and human
brain slices, we have increased the concentration of 4-CIN to 500 µM. Although this concentration
readily decreased stimulus induced ∆pO2 from 14.6 ± 0.8 to 10.4 ± 0.6 mmHg (Figure 1C; Wilcoxon
signed rank test, p < 0.001, n = 9, 5 patients), the amplitude of the evoked field potential response and
the recovery kinetics of ∆[K+]O remained unaltered (Figure 1E,G), thereby suggesting a difference in
lactate use between chronic epileptic human and rat brain slices.
2.2. 4-CIN Reduced Incidence of Seizure-Like Events (SLEs) in Neocortical Slices from Patients with mTLE
Ictal increases in extracellular lactate levels have been described during acute provoked seizures
in otherwise healthy brain slices and also in chronic epileptic tissue [29]. Surplus lactate could serve as
a substrate to cover enhanced oxidative metabolism during seizure activity, whereas the acidotic shift
associated with lactate accumulation have been speculated to contribute to the termination of seizures.
Epileptiform activity, resembling seizure like events (SLEs), interictal and recurrent discharges can be
readily induced in resected human neocortical slices by applying a combination of the GABAA receptor
inhibitor bicuculline methiodide (50 µM) along with an increased K+ (8 mM) containing aCSF [30].
After attaining stable recurrent SLEs (first SLE appeared with a latency of 8.4 ± 4.0 min), 500 µM
4-CIN was applied for 30 min and the incidence, amplitude and duration of SLEs were evaluated.
Inhibition of MCTs significantly reduced SLE incidence from 5.9 ± 0.9 to 2 ± 0.4 (Figure 2A,B; paired
t-test, p < 0.01, n = 9 slices, 4 patients) and amplitude from 1.0 ± 0.1 to 0.9 ± 0.1 mV (Figure 2A,D;
paired t-test, p <0.01, n = 9 slices, 4 patients) while it did not change SLE duration of the last 10 min
recordings for each condition (Figure 2A,C). Notably, the effect of 4-CIN developed slowly reaching its
maximum at the end of 4-CIN application. The decrease in incidence and amplitude was not due to
a time dependent general decline in the propensity of the slices to generate SLEs as these parameters
(incidence and amplitude) partially recovered following washout of 4-CIN to 3.4 ± 1.9 (Figure 2A,B;
paired t-test, p < 0.05, n = 9 slices, 4 patients).
2.3. Lactate Uptake Inhibitors Decreased the Incidence of Pharmacologically Induced Burst Discharges and
SLEs in Rat Entorhinal Cortex-Hippocampus Slices
In the next set of experiments, we determined whether the anti-seizure effect of 4-CIN was
specific to chronic epileptic tissue or it represents a general consequence of MCT inhibition. Likewise,
we induced SLEs in rat medial entorhinal cortex by applying the voltage gated potassium channel
blocker, 4-aminopyridine (4-AP, 50 µM). Application of 4-CIN (200 µM) after establishing regular
SLEs (with a latency of 21.8 ± 8.6 min) completely stopped SLEs in 2 slices out of 10 and in the rest
it decreased SLE incidence from 2.1 ± 0.1 to 1.1 ± 0.1 during the last 10 min of the control and drug
exposure phases (Figure 2E,F; Wilcoxon signed rank test, p < 0.01, p = 8, 4 rats) and seizure duration
from 1.8 ± 0.4 to 0.9 ± 0.3 s (Figure 2E,G; paired t-test, p < 0.01, p = 8, 4 rats), whereas it did not affect
the amplitude of SLEs (Figure 2E,H). Increasing the concentration of 4-CIN to 500 µM, as applied to
human brain slices, ceased the SLEs in all slices. Notably, there was a complete recovery upon washout
(n = 8, 4 rats).
In order to exclude that the observed anti-seizure effect would depend on the type of
pro-convulsive treatment (bicuculline in human, 4-AP in rat), we also extended the study to bicuculline
induced epileptiform activity in rat hippocampus slices. Inhibition of GABAA receptors have been
shown to induce recurrent epileptiform discharges (REDs) of shorter duration rather resembling
interictal burst activity than of the SLEs induced by 4-AP [31]. By applying 5 µM bicuculline, we were
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able to induce REDs in the area CA3 with an amplitude of 6.1 ± 1.4 mV (Figure 3A,C), duration of
124 ± 7 ms (Figure 3A,D) and incidence of 10.4 ± 1.8/min (Figure 3B; n = 7, 3 rats). Application of
200 µM 4-CIN completely ceased REDs. During washout the incidence partially recovered while the
amplitude and duration undertook complete recovery (Figure 3A–D). Thus blocking lactate uptake
exerts an anti-seizure effect irrespective of the proconvulsive treatment (4-AP, bicuculline, bicuculline
plus elevated potassium), species and anatomical structure (human neocortex vs. rat entorhinal
cortex—hippocampus slices) as well as the type of the tissue (chronic epileptic vs. healthy control).
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excerpt showing a single seizure like event on different time scale; (F) Application of 4-CIN decreased 
incidence and (G) duration of SLEs without affecting (H) amplitude. (B–D,F–H) Variables are given 
on the Y-axis, categories of treatment on the X-axis. ** p < 0.01. Each dot represents a single data point, 
black dots represent control condition (seizure induction), red dots represent 4-CIN application on 
top of seizure inducing drugs, and blue dots represent washout phase. 
Figure 2. Effects of 4-CIN on sponta t ileptiform activity induced by levated
potassium plus bicucul ine i i l slices from mesial temporal lobe ile sy patients (mTLE)
or i t ial e torhinal cortex (MEC) slices. (A) Sample field potential trace repr se ting
recurrent SLEs during induction (left) 4-CI i dle) and wash out (right) i ne cortical
slices from TLE patients, the (a) excer t i si gle seizure like event on diff rent time scale;
(B) Application f 4-CIN significantly decreased incidence of SLEs (C) without affecting eve t duration
(D) but also decreased FP amplitude; (E) Sample field potential trace during seizure induction (left)
4-CIN application (middle) and wash out (right) in MEC slices from rat, (a) the excerpt showing
a single seizure like event on different time scale; (F) Application of 4-CIN decreased incidence and
(G) duration of SLEs without affecting (H) amplitude. (B–D,F–H) Variables are given on the Y-axis,
categories of treatment on the X-axis. ** p < 0.01. Each dot represents a single data point, black dots
represent control condition (seizure induction), red dots represent 4-CIN application on top of seizure
inducing drugs, and blue dots represent washout phase.
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acidotic shift of 0.17 ± 0.01 pH unit also in the presence of 4-AP induced epileptiform activity in rat 
entorhinal cortex slices [22]. Each seizure like event (SLE) was associated with a corresponding 
acidotic shift (Figure 4C). Although the amplitude of individual SLE-associated pH transients 
decreased during the 4-CIN induced pH shift, this might be simply a consequence of the 
simultaneous decrease of SLE duration (Figure 4A) rather than a consequence of a genuine change in 
metabolism. In the subsequent set of experiments D-lactate (20 mM) application following 
establishment of recurrent SLEs reduced SLE incidence/10 min from 3.6 ± 0.6 to 2.1 ± 0.4 (Figure 4D; 
paired t-test, p < 0.05, n = 8, 4 rats) and SLE duration from 0.78 ± 0.2 to 0.24 ± 0.1 min (Figure 4E; 
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Figure 3. Effect of MCT inhibition by 4-CIN on recurrent epileptiform discharges (REDs) induced by
pharmacological blockade of GABAA receptors. (A) Sample traces of bicuculline induced REDs before
(left, a), during (middle, b) and after 4-CIN application (right, c). Single RED trace during baseline (1)
and washout (2). 4-CIN completely stopped REDs and the effect on (B) incidence (C) amplitude and (D)
frequency was partly reversed during washout; (B–D) Variables are given on the Y-axis, categories of
treatment on the X-axis. Each dot represents a single data point, black dots represent 5 µM bicuculline
a plication, red dots represent 200 µM 4-CIN and 5 µM bicuculline application, blue dots represent
washout in 5 µM bicuculline.
2.4. Anti-Epileptic Effect of 4-CIN Is Mediated by Adenosine through A1 Receptor But Not by Acidosis
In our previous paper, we have shown that 4-CIN induces extracellular acidosis due to
parenchymal lactate accumulation (Figure 4A) [22]. Whether or not this acidosis could contribute to
the observed anti-seizure effect was tested by using D-lactate, the non-metabolisable isoform, to inhibit
lactate transport. As it competes with L-lactate on all types of MCTs, both for release and uptake,
no net lactate accumulation occurs in the parenchyma and consequently no extracellular acidosis is
expected (Figure 4B). In line with our previous findings, application of 4-CIN led to an acidotic shift
of 0.17 ± 0.01 pH unit also in the presence of 4-AP induced epileptiform activity in rat entorhinal
cortex slices [22]. Each seizure like event (SLE) was associated with a corresponding acidotic shift
(Figure 4C). Although the amplitude of individual SLE-associated pH transients decreased during
the 4-CIN induced pH shift, this might be simply a consequence of the simultaneous decrease of SLE
duration (Figure 4A) rather than a consequence of a genuine change in metabolism. In the subsequent
set of experiments D-lactate (20 mM) application following establishment of recurrent SLEs reduced
SLE incidence/10 min from 3.6± 0.6 to 2.1± 0.4 (Figure 4D; paired t-test, p < 0.05, n = 8, 4 rats) and SLE
duration from 0.78 ± 0.2 to 0.24 ± 0.1 min (Figure 4E; Wilcoxon signed rank test, p < 0.05, n = 8, 4 rats)
without affecting the baseline pH. SLE amplitude was slightly decreased as well but it did not reach
significance within the timeframe of the application (Figure 4F). The decrease in SLE amplitude and
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duration was also reflected in the decrease of the SLE-associated acidotic pH transients, despite the
absence of a baseline pH change (n = 6, 3 rats). Similar to the anti-seizure effect of 4-CIN, the decrease
in incidence and duration was reversible upon washout of D-lactate. Thus, acidosis induced by lactate
accumulation cannot be a sole cause of the negative impact of MCT inhibition on seizure incidence.
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Figure 4. Effect of MCT inhibitors—4-CIN and D-lactate—on baseline and SLE-associated changes
in extracellular pH. Extracellular H+ ion concentration was measured using ion sensitive electrodes;
hence the displayed traces show change in H+ ion concentration which got converted to pH units.
(A) Application of 4-CIN resulted in a late onset baseline acidotic shift; (B) In contrast, application of
sodium D-lactate (20 mM, osmolality and pH set as in normal aCSF) did not induce changes in baseline
pH while exerting similar inhibitory effects on 4-AP induced epileptic form activity; (C) Sample trace of
single SLE with corresponding pH change in different time scale. Each individual SLE was associated
with small acidotic shifts in both 4-CIN (1,2) and D-lactate (3,4) experiments, traces taken from the
recordings in (A,B) as shown by the corresponding number; (D) SLE incidence and (E) duration (F) but
not the amplitude were significantly decreased; (D–F) Variables are given on the Y-axis, categories of
treatment on the X-axis. * p < 0.05. Each dot represents a single data point, black dots represent 50 µM
4-aminopyridine (4-AP) application, red dots represent 20 mM D-lactate and 50 µM 4-AP application,
blue dots represent washout in 50 µM 4-AP.
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The decrease in stimulus-induced ∆pO2 upon MCT inhibition evidenced a significant contribution
of lactate to oxidative metabolism both in chronic epileptic tissue and in hippocampal slices from the
rat. Conditions leading to net hydrolysis of ATP increase adenosine level which plays a neuroprotective
role by suppressing excitatory neurotransmission through A1 receptors [32,33]. Seizures represent
a metabolic burden leading to activation of oxidative metabolism [34,35] and increase in extracellular
adenosine concentration [36], which exerts antiepileptic effects even in otherwise pharmacoresistant
mTLE tissue [36]. Lactate uptake inhibitors with an effect on oxidative metabolism will presumably
augment changes in extracellular adenosine. Hence, we tested whether the anti-seizure effect
of 4-CIN and D-lactate is mediated by activation of the A1 receptor. The specific A1 antagonist,
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX, 0.1 µM), was co-applied with 4-CIN following the
establishment of recurrent SLEs in the presence of 4-AP. Although the SLE incidence was still slightly
reduced from 3.3 ± 0.98 to 2.0 ± 0.4 during the concomitant application of 4-CIN and DPCPX,
this change did not reach significance (Figure 5A,B; Wilcoxon signed rank test, p = 0.06, n = 9, 4
rats). Neither SLE duration (1.1 ± 0.2 vs. 1.4 ± 0.4 min; Figure 5C; Wilcoxon signed rank test, p = 0.2,
n = 9, 4 rats) nor the SLE amplitude (1.5 ± 0.2 vs. 1.4 ± 0.2 mV; Figure 5D; paired t-test, p = 0.3,
n = 9, 4 rats) were different from the control if 4-CIN and DPCPX were applied simultaneously to the
aCSF. Notably, DPCPX application in the absence of 4-CIN exacerbated 4-AP induced epileptiform
activity, suggesting that A1 receptor activation contributes to normal SLE termination and this effect
might be augmented following inhibition of lactate transport. Thus, the partial reversal of the
antiepileptic effect of 4-CIN by DPCPX proved that the contribution of lactate to the oxidative energy
metabolism exerts a pro-seizure effect.
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3. Discussion 
The main finding of the study was that inhibition of MCT mediated lactate transport exerts an 
anti-seizure effect via restriction of the oxidative energy metabolism and subsequent activation of A1 
receptors. In contrast, acidotic shift of the tissue pH was dispensable for the effect as it could be 
repeated by application of D-lactate, which did not result in acidosis. Remarkably, the anti-seizure 
. i i i i i i i i .
( ) li ti f t e 1 antagonist 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) in p rallel with
4-CIN partially reversed th effect of MCT inhibitor on SLE (B) incidence (C) duration ( ) lit .
ari les re i e t e -a is, c te ries f tre t e t t e - is. c t re rese ts si le
ata oi t, black ots re rese t 50 4-a i o yri i e (4- ) a licatio , re ots re rese t 5
P P and 50 µ 4- P application.
fi i of the study was that inhib tion of MCT mediated lacta e transport exerts
anti-seizure ffect via restricti n of the oxidative energy metabolism and subsequent activati n of
Int. J. Mol. Sci. 2017, 18, 1835 9 of 15
A1 receptors. In contrast, acidotic shift of the tissue pH was dispensable for the effect as it could be
repeated by application of D-lactate, which did not result in acidosis. Remarkably, the anti-seizure
effect could be observed both in chronic epileptic brain slices from TLE patients and in entorhinal
cortex-hippocampus slices from rats irrespective of the type of the pro-convulsive treatment. Despite
the negative effect of the inhibition of MCTs on the oxidative energy metabolism, the recovery of the
stimulus induced ion transients did not depend on neuronal lactate uptake in epileptic human cortex
tissue, which is in contrast to the findings in rat hippocampus slices [22].
Application of the lactate uptake inhibitor in the hippocampus decreased oxygen consumption
and induced an over-oxidation of nicotinamide adenine dinucleotide (NADH) and flavin adenine
dinucleotide (FADH2) pools, indicating that lactate is being used as oxidative energy substrate even in
the presence of ample glucose [11,13,22]. Lactate derived ATP was used by ion transport mechanisms
and for maintenance of postsynaptic signaling [22]. The changes in the MCT expression pattern
observed in epilepsy patients as well as in animal models of epilepsy might hint to an altered use
of lactate in chronic epileptic tissue [25–28]. While the increased expression of MCT1 and MCT2
in the neuropil may be the consequence of enhanced astrocytic anaerobic metabolism, the loss of
MCT4 on astrocyte endfeet and of MCT1 on endothelial cells might indicate an impaired clearance
into the bloodstream. These changes would favor the elevated lactate levels under conditions of
enhanced neuronal activity when the brain is a net producer of lactate [37]. Taking into account the
mitochondrial dysfunction in chronic epileptic tissue [38–40], whether this lactate is used as a substrate
for oxidative metabolism in neurons is not known [24]. In our hands, MCT inhibition had a clear
effect on stimulus induced pO2 changes in chronic epileptic tissue, pointing the relevance of lactate
for oxidative energy metabolism. However, neither the amplitude of the field potentials nor the
recovery kinetics of stimulus induced ion transients were altered, suggesting that these processes are
not dependent on lactate derived ATP. Unfortunately, the effect of 4-CIN on the postsynaptic action
potential generation might be underestimated in our model as the field potentials in the neocortical
layers V/VI did not allow the clear discrimination of anti- and orthodromic population spikes and
antidromic action potentials were insensitive to 4-CIN also in the rat hippocampus [22].
The most striking effect of the MCT inhibition was a decrease in the incidence of epileptiform
activity up to a complete block of SLEs, irrespective of the type of the proconvulsant, i.e., 4AP,
bicuculline and elevated potassium. In addition to its potential role in oxidative metabolism,
an anti-seizure effect of ictal lactic acidosis has been suggested in numerous studies [41,42].
The mechanisms by which low pH may exert an anti-seizure effect might include (i) negative
modulation of the N-methyl-D-aspartate (NMDA) receptor currents, (ii) inhibition of presynaptic
voltage gated Ca2+ channels as well as (iii) facilitation of ecto-ATPases or increased adenosine
release [41–44]. Indeed, the acidosis following 4-CIN application was associated with decreased
incidence and duration of SLEs both in chronic epileptic and healthy rat brain slices. However,
the anti-seizure effect was preserved also in the presence of D-lactate, which did not induce acidosis,
likely due to the fact that D-lactate non-selectively inhibits both, uptake and release of lactate [13].
Thus, while acidosis is not responsible for the observed anti-seizure effect of D-lactate, it might still
contribute to seizure suppression in the case of the 4-CIN treatment.
Elevated lactate by itself might alter neuronal excitability irrespective of the change in pH by
acting on its G-protein coupled receptor HCA1, which reduces cellular cAMP levels [45] and inhibits
action potential generation [46]. However, in our previous study the HCA1 agonist 3,5,DHBA increased
orthodromic responses and stimulus associated pO2 changes which is not compatible with the expected
inhibitory effect [22]. Therefore we would expect that—at least in rat brain slices—HCA1 activation is
not likely to contribute to the inhibitory effect of parenchymal lactate accumulation.
Another possibility for an anti-seizure effect could be an increase in extracellular adenosine
concentration, as a consequence of enhanced neuronal energy consumption in the presence of
a partial metabolic restriction and pH dependent activation of ecto-ATPases. It has been reported
previously that activity dependent basal adenosine tone modulates seizure activity [47,48] in a pH
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dependent manner [49] and individual seizures are associated with increased extracellular adenosine
concentrations [36,50]. In general, increased adenosine levels contributed to the suppression of synaptic
activity following events associated with metabolic stress such spreading depression [51], hypoxia [52],
inhibition of glycolysis by 2-deoxy-D-glucose [53]. Indeed, application of the A1 receptor antagonist
DPCPX was able to recover the effect of MCT inhibition on SLE duration and incidence. DPCPX alone
exacerbated 4AP induced recurrent SLEs, suggesting that activity dependent adenosine increases
might mediate seizure termination and this mechanism is augmented by restricted lactate availability.
With respect to chronic epileptic tissue the relevance of A1 receptor modulation might be even larger as
the enzyme adenosine kinase, which contributes to the termination of adenosine effects, is upregulated
in astrocytes [54,55]. Indeed, application of a non-metabolisable A1 agonist could reverse recurrent
epileptiform activity even in otherwise pharmacoresistant tissue [56].
Alternatively, substrate deprivation by MCT inhibition might also led to the activation of KATP
channels, which sense the absence of lactate derived ATP, leading to hyperpolarization and suppression
of postsynaptic action potential generation [22]. Whether, in our model inhibiting activation of KATP
channels would be able to reverse the inhibitory effect of 4-CIN remains to be determined.
Restriction of oxidative energy metabolism by 2-deoxy-D-glucose, which also affects the lactate
synthesis pathways, has been shown to have anti-epileptic effect in acute provoked seizures both
in vivo and in vitro [57,58] but led to epileptogenesis in others [59]. Sada et al. 2015 has shown that
inhibition of lactate dehydrogenase hyperpolarizes neurons and suppresses seizure in vivo which
prompts the importance of lactate in modulating neuronal excitability [60]. Taken together these
findings suggest that ictal increases in parenchymal lactate concentrations in chronic epileptic tissue
are rather pro- than antiepileptic by supporting seizure associated energy metabolism.
Dietary modifications, like ketogenic diet, has been considered as an alternate treatment for certain
types of drug resistant epilepsy but the mechanism of anti-epileptic action remain largely unknown [61].
One of the effects of ketogenic diet has been attributed to inhibition of glycolysis [62] which might
result in a similar effect as MCT inhibition in our study. Another documented cellular adaptation
in rats is an increase in the transport capacity of ketone bodies across the blood brain barrier [63],
via upregulation of MCT1 expression on the brain endothelium [64]. Based on our findings, one could
argue that the ketogenic diet likely restores and perhaps even increases the clearance of lactate under
conditions when brain is a net producer, thereby limiting the availability of a potential energy resource.
4. Material and Methods
4.1. Slice Preparation
Animal experiments were performed on slices from 25 Wistar rats (180–250 g) in accordance
with the Helsinki declaration and institutional guidelines (as approved by the State Office of Health
and Social Affairs, Berlin, Germany, Lageso, T0096/02) and the animal welfare regulations of Charité.
Animals were decapitated under deep anesthesia with isoflurane (3% vol/vol) and laughing gas
(70% N2O, 30% O2). Horizontal hippocampal slices (400 µm thick) were prepared and transferred to
an interface chamber perfused with artificial cerebrospinal fluid (aCSF) carbogenated with 95% O2,
5% CO2, at a rate of 2 mL/min. The aCSF solution is composed of NaCl (129), NaHCO3 (21 mM),
glucose (10 mM), KCl (3 mM), NaH2PO4 (1.25 mM), CaCl2 (1.6 mM) and MgCl2 (1.8 mM) with
an osmolarity of 295–305 mOsm.
The study in resected human tissue was performed after receiving written informed
consent from epilepsy patients. All experiments were approved by the Ethics Committee of
Charité-Universitätsmedizin Berlin on 01.11.2014 (EA2/111/14) and were in agreement with the
Declaration of Helsinki. Transport, slicing and maintenance of the human tissue samples was carried
out as described previously [30,56]. Immediately after surgery, the resected tissue was transferred
to cold carbogenated transport solution (95% O2, 5% CO2) composed of (in mM) KCl 3, NaH2PO4
1.25, glucose 10, sucrose 200, MgSO4 2, MgCl2 1.6, CaCl2 1.6, and α-tocopherol 0.1 (pH 7.4, osmolality,
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304 mOsmol/kg). 500 µM thick slices were prepared in transport solution and transferred to interface
chamber perfused with carbogenated aCSF as specified above at a rate of 2 mL/min. Slices were left to
recover for 4 h before starting an experiment.
4.2. Electrophysiology and Oxygen Recordings
DC coupled field potential, extracellular K+ ([K+]O) and pH measurements were done in
layer V/VI of human neocortex and rat medial entorhinal cortex as well as in the CA3 area of
the hippocampus using double barreled ion sensitive microelectrodes prepared as described in
Angamo et al., 2016 [22]. For pH electrodes, the H+ sensitive side was filled with a solution consisting
of (mM) 500 KCl, 64.7 NaH2PO4, and 85.3 Na2HPO4 (pH 7), while the reference side was filled with
500 mM KCl [22]. For K+ sensitive electrodes, the ion sensitive and the reference barrel were filled
with 100 mM KCl and 154 NaCl solutions respectively. Then, the ion sensitive sides of K+ and H+
sensitive microelectrodes were tip filled with Potassium Ionophore I. 60031 and Hydrogen Ionophore
II., Cocktail A (Fluka, Buchs, Switzerland) respectively. The sensitivity of the electrodes was tested with
a tenfold calibration solution before use. Extracellular changes in K+ and pH were calculated using
the modified Nernst equation [22]. Oxygen tension (pO2) was measured using the Clark-style oxygen
sensor microelectrodes (tip: 10 µm; Unisense, Aarhus, Denmark) which were polarized overnight and
calibrated in aCSF solution saturated with 20 and 95% O2. For stimulus induced responses, a bipolar
platinum wire electrode was positioned in the white matter and a 20 Hz stimulus train was applied
for 2 s every 4 min with an intensity giving rise of 80% of the maximal response. Data were recorded
by using either a home-built differential amplifier for the ion-sensitive electrode or a polarographic
amplifier (Chemical Microsensor II; Diamond General Development). Signals were digitized and
recorded with a CED-1401 interface and the software Spike2 (Cambridge Electronic Design, Cambridge,
UK) at 10 kHz for field potential and 1 kHz for potassium, pH and oxygen concentration.
4.3. Pharmacology
To inhibit the monocarboxylate transporters we used either 4-CIN (200 µM, 500 µM) or the
non-metabolisable isomer sodium D-lactate (20 mM). Sodium D-lactate solution was prepared in
a special aCSF with a NaCl concentration adjusted to compensate for the osmolarity change. pH of
the NaHCO3/CO2 buffer system was set to 7.3 in bubbled aCSF prior to the recording. Epileptiform
activity in human neocortex slices was induced by using elevated K+ (8 mM) aCSF solution and 50 µM
bicuculline methiodide in the perfusion while in rat brain slices either 50 µM 4-aminopyridine (4-AP)
or 5 µM bicuculline methiodide was added to the aCSF. The A1 receptor antagonist DPCPX was used
at a concentration of 0.1 µM. All chemicals were bought from Sigma-Aldrich (Taufkirchen, Germany).
4.4. Data Analysis
The last 10 min recordings for each experimental condition (control, MCT inhibitor, and washout)
were used to compare incidence, maximum amplitude including fast transients and duration of seizure
like events in rat and human neocortex. For stimulus induced responses, we assessed the effect of
4-CIN on extracellular K+ concentration, K+ first half decay time, field potential responses and pO2.
The first half decay time represents the time needed for K+ to reach half maximum concentration.
To assess amplitude of field potential recordings in-built spike script is used; peak to point of maximum
deflection is measured. The last 3 recordings (data points) during baseline and 4-CIN application
were used for analysis. Data are presented as mean ± SEM, with a scatter plot where all values
are displayed. Analysis was done using spike script and Graphipad Prism. The distribution of the
data was tested for normality using D’Agostino and Pearson omnibus normality test; subsequently,
t-test and Wilcoxon signed rank test were used for statistical comparison for data with normal and
non-normal distribution, respectively.
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